



**Maidstone and  
Tunbridge Wells**  
NHS Trust

Ref: FOI/GS/ID 6458

**Please reply to:**  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone, Kent  
ME16 9QQ  
Email: [mtw-tr.foiadmin@nhs.net](mailto:mtw-tr.foiadmin@nhs.net)  
[www.mtw.nhs.uk](http://www.mtw.nhs.uk)

05 January 2021

## **Freedom of Information Act 2000**

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Myelofibrosis and Oesophageal cancer.

*You asked:*

*Q1. Does your trust treat the following conditions? If not, which other trust do you refer these patients to?*

- a. Advanced oesophageal cancer*
- b. Myelofibrosis*

*Q2. Please provide the total number of patients treated in the last 6 months for:*

- a. Myelofibrosis*
- b. Myelofibrosis – patients over the age 65*
- c. Oesophageal cancer (any type)*
- d. Oesophageal adenocarcinoma*
- e. Oesophageal squamous cell carcinoma*
- f. Unresectable Oesophageal squamous cell carcinoma*

*Q3. For the oesophageal squamous cell carcinoma patients only, how many patients were treated in the past 6 months with?*

- a. Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)*
- b. Any other systemic anti-cancer therapy*
- c. Palliative care only*

*Q4. For myelofibrosis patients only, how many patients (of any age) were treated in the past 6 months with?*

- a. Ruxolitinib*
- b. Hydroxyurea*
- c. Watch and wait approach*

Q5. Does your trust participate in any clinical trials for oesophageal cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Q6. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part?

Trust response:

Q1.

a. Yes

b. Acute Myelofibrosis is a cancer recorded on our system, but is part of a wider group called Myeloproliferative disorders, so we would not be able to break that down any further to just pick up acute myelofibrosis.

Q2.

a. Please see response to Q1b

b. Please see response to Q1b

Please note: Q1 refers to Advanced Oesophageal cancer, but Q2 does not say Advanced. Therefore, in answering these questions, we have shown the number Advanced patients in brackets (as per the Cancer Research website which denotes this as a cancer that has spread elsewhere in the body, so we have used patients whose M staging is not 0)

c. 43 (5)

d. 19 (3)

e. 10 (1)

f. This is not recorded on our system

Q3.

a. 2

b. 3

c. 5 (0)

Q4. Please see response to Q1b

Q5. SCOPE 2 (3 patients recruited)

A randomised Phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemoradiation with an embedded Phase II trial for patients with a poor early response using positron emission tomography (PET)

IRAS Number: 169633

Add-Aspirin (includes Oesophageal cancer patients, 72 patients recruited across all cancers)

A phase III double-blind placebo-controlled randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.

IRAS Number: 120104

CA209-76A (EAMS) (no patients recruited yet, opened Nov 2020)

CLINICAL CHARACTERISTICS, OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH SQUAMOUS CELL OESOPHAGEAL CARCINOMA RECEIVING NIVOLUMAB AFTER PRIOR CHEMOTHERAPY AS PART OF

AN EARLY ACCESS TO MEDICINES SCHEME (EAMS) PROGRAM IN THE  
UNITED KINGDOM  
IRAS Number: 272203  
Q6. Not currently.